# BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q2 P&L / Income Statement - Company: BOSTON SCIENTIFIC CORPORATION (BSX) - Period: 2026-04-01 to 2026-06-30 - Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0000885725-26-000053 - Page: https://plicit.ai/financials/bsx/fy2026-q2-income-statement - Chart image: https://plicit.ai/charts/bsx-fy2026-q2-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,442,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,594,000,000 US dollars - **Gross profit**: 3,848,000,000 US dollars - **Operating expenses**: 2,670,000,000 US dollars - **Operating income (loss)**: 1,178,000,000 US dollars - **Other income (expense), net (calculated)**: negative 118,000,000 US dollars - **Income (loss) before income taxes**: 1,060,000,000 US dollars - **Income tax expense (benefit)**: 155,000,000 US dollars - **Net income (loss)**: 905,000,000 US dollars - **Cardiac Rhythm Management - UNITED STATES**: 349,000,000 US dollars - **Cardiac Rhythm Management - Int'l**: 236,000,000 US dollars - **Electrophysiology - UNITED STATES**: 606,000,000 US dollars - **Electrophysiology - Int'l**: 310,000,000 US dollars - **Endoscopy - UNITED STATES**: 491,000,000 US dollars - **Endoscopy - Int'l**: 303,000,000 US dollars - **Neuromodulation - UNITED STATES**: 257,000,000 US dollars - **Neuromodulation - Int'l**: 84,000,000 US dollars - **Urology - UNITED STATES**: 503,000,000 US dollars - **Urology - Int'l**: 181,000,000 US dollars - **Interventional Cardiology & Vascular Therapies - UNITED STATES**: 586,000,000 US dollars - **Interventional Cardiology & Vascular Therapies - Int'l**: 746,000,000 US dollars - **Interventional Oncology & Embolization - UNITED STATES**: 175,000,000 US dollars - **Interventional Oncology & Embolization - Int'l**: 108,000,000 US dollars - **Watchman - UNITED STATES**: 459,000,000 US dollars - **Watchman - Int'l**: 48,000,000 US dollars - **Selling, general and administrative expenses**: 1,803,000,000 US dollars - **Research and development expenses**: 554,000,000 US dollars - **Royalty expense**: 12,000,000 US dollars - **Amortization expense**: 233,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 16,000,000 US dollars - **Restructuring net charges (credits)**: 8,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $907.00 M; to noncontrolling interests: −$2.00 M. ## Chart details: Revenue by Business Segment - Page: https://plicit.ai/financials/bsx/fy2026-q2-income-statement/revenue-by-business-segment - Chart image: https://plicit.ai/charts/bsx-fy2026-q2-revenue-by-business-segment-sankey.png Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,442,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,594,000,000 US dollars - **Gross profit**: 3,848,000,000 US dollars - **Operating expenses**: 2,670,000,000 US dollars - **Operating income (loss)**: 1,178,000,000 US dollars - **Other income (expense), net (calculated)**: negative 118,000,000 US dollars - **Income (loss) before income taxes**: 1,060,000,000 US dollars - **Income tax expense (benefit)**: 155,000,000 US dollars - **Net income (loss)**: 905,000,000 US dollars - **MedSurg**: 1,818,000,000 US dollars - **Cardiovascular**: 3,624,000,000 US dollars - **Selling, general and administrative expenses**: 1,803,000,000 US dollars - **Research and development expenses**: 554,000,000 US dollars - **Royalty expense**: 12,000,000 US dollars - **Amortization expense**: 233,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 16,000,000 US dollars - **Restructuring net charges (credits)**: 8,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $907.00 M; to noncontrolling interests: −$2.00 M. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/bsx/fy2026-q2-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/bsx-fy2026-q2-revenue-by-geography-sankey.png Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,442,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,594,000,000 US dollars - **Gross profit**: 3,848,000,000 US dollars - **Operating expenses**: 2,670,000,000 US dollars - **Operating income (loss)**: 1,178,000,000 US dollars - **Other income (expense), net (calculated)**: negative 118,000,000 US dollars - **Income (loss) before income taxes**: 1,060,000,000 US dollars - **Income tax expense (benefit)**: 155,000,000 US dollars - **Net income (loss)**: 905,000,000 US dollars - **UNITED STATES**: 3,426,000,000 US dollars - **Int'l**: 2,017,000,000 US dollars - **Selling, general and administrative expenses**: 1,803,000,000 US dollars - **Research and development expenses**: 554,000,000 US dollars - **Royalty expense**: 12,000,000 US dollars - **Amortization expense**: 233,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 16,000,000 US dollars - **Restructuring net charges (credits)**: 8,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars - **Revenue before reconciliation (calculated)**: 5,443,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $907.00 M; to noncontrolling interests: −$2.00 M. ## Chart details: Revenue by Product and Service - Page: https://plicit.ai/financials/bsx/fy2026-q2-income-statement/revenue-by-product-and-service - Chart image: https://plicit.ai/charts/bsx-fy2026-q2-revenue-by-product-and-service-sankey.png Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,442,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,594,000,000 US dollars - **Gross profit**: 3,848,000,000 US dollars - **Operating expenses**: 2,670,000,000 US dollars - **Operating income (loss)**: 1,178,000,000 US dollars - **Other income (expense), net (calculated)**: negative 118,000,000 US dollars - **Income (loss) before income taxes**: 1,060,000,000 US dollars - **Income tax expense (benefit)**: 155,000,000 US dollars - **Net income (loss)**: 905,000,000 US dollars - **Endoscopy**: 793,000,000 US dollars - **Urology**: 684,000,000 US dollars - **Neuromodulation**: 341,000,000 US dollars - **Interventional Cardiology & Vascular Therapies**: 1,333,000,000 US dollars - **Watchman**: 507,000,000 US dollars - **Electrophysiology**: 916,000,000 US dollars - **Cardiac Rhythm Management**: 585,000,000 US dollars - **Interventional Oncology & Embolization**: 283,000,000 US dollars - **Selling, general and administrative expenses**: 1,803,000,000 US dollars - **Research and development expenses**: 554,000,000 US dollars - **Royalty expense**: 12,000,000 US dollars - **Amortization expense**: 233,000,000 US dollars - **Intangible asset impairment charges**: 0 US dollars - **Contingent consideration net expense (benefit)**: negative 16,000,000 US dollars - **Restructuring net charges (credits)**: 8,000,000 US dollars - **Litigation-related net charges (credits)**: 76,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $907.00 M; to noncontrolling interests: −$2.00 M.